Science - USA (2020-05-22)

cells may become important in situations of
transient and multiple interactions, where de-
livery might be less precise. SMAPs may have
other modes of action, potentially including
chemoattraction through C-C motif chemo-
kine ligand 5 (CCL5, or RANTES) and immune
modulation through interferon-g. The TSP1 C
terminus contains the binding site for the ubiq-
uitous“don’teatme”signal CD47 ( 32 ). SMAPs
may thus partner with macrophages to ensure
that any cell that cannot be killed by SMAPs is
culled by phagocytosis ( 33 ).

REFERENCES AND NOTES

1. D. Masson, J. Tschopp,Cell 49 , 679–685 (1987).


2. J. Tschopp, S. Schäfer, D. Masson, M. C. Peitsch, C. Heusser,
   Nature 337 , 272–274 (1989).


3. J. C. Stinchcombe, G. Bossi, S. Booth, G. M. Griffiths,Immunity
   15 , 751–761 (2001).


4. G. Ménasché, J. Feldmann, A. Fischer, G. de Saint Basile,
   Immunol. Rev. 203 , 165–179 (2005).


5. M. Kaloset al.,Sci. Transl. Med. 3 , 95ra73 (2011).


6. C. J. Froelichet al.,J. Biol. Chem. 271 ,29073–29079 (1996).


7. D. Keefeet al.,Immunity 23 , 249–262 (2005).


8. R. H. Lawet al.,Nature 468 , 447–451 (2010).


9. S. S. Metkaret al.,Immunity 16 , 417–428 (2002).


10. J. A. Martinaet al.,Cell. Immunol. 271 , 267–279 (2011).


11. P. J. Peterset al.,Eur. J. Immunol. 19 , 1469–1475 (1989).


12. P. J. Peterset al.,J. Exp. Med. 173 , 1099–1109 (1991).


13. L. Luginiet al.,J. Immunol. 189 , 2833–2842 (2012).


14. F. Bertrandet al.,Proc. Natl. Acad. Sci. U.S.A. 110 , 6073– 6078

(2013).

15. W.T. Kimet al.,Proc. Natl. Acad. Sci. U.S.A. 99 , 17143– 17148
    (2002).


16. R. Kornfeld, S. Kornfeld,Annu. Rev. Biochem. 54 , 631– 664
    (1985).


17. G. M. Griffiths, S. Isaaz,J. Cell Biol. 120 , 885–896 (1993).


18. K. Somersaloet al.,J. Clin. Invest. 113 ,49–57 (2004).


19. J. C. Kuo, X. Han, C. T. Hsiao, J. R. Yates 3rd, C. M. Waterman,
    Nat. Cell Biol. 13 , 383–393 (2011).


20. M. Kvansakul, J. C. Adams, E. Hohenester,EMBO J. 23 ,
    1223 – 1233 (2004).


21. T. M. Misenheimer, D. F. Mosher,J. Biol. Chem. 270 , 1729– 1733
    (1995).


22. E. R. Podack, P. J. Konigsberg,J. Exp. Med. 160 , 695– 710
    (1984).


23. D. S. Annis, J. E. Murphy-Ullrich, D. F. Mosher,J. Thromb.
    Haemost. 4 , 459–468 (2006).


24. S. S. Liet al.,Eur. J. Immunol. 32 , 1069–1079 (2002).


25. G. Schneider,Ultramicroscopy 75 ,85–104 (1998).


26. M. Harkiolakiet al.,Emerg. Top. Life Sci. 2 ,81–92 (2018).


27. G. Bossi, G. M. Griffiths,Nat. Med. 5 ,90–96 (1999).


28. K. Choudhuriet al.,Nature 507 , 118–123 (2014).
    29.D. G. Salibaet al.,eLife 8 , e47528 (2019).
    30.E.Cocucci,J.Meldolesi,Trends Cell Biol. 25 ,364– 372
    (2015).


29. S. Halleet al.,Immunity 44 , 233–245 (2016).


30. V. Mateoet al.,Nat. Med. 5 , 1277–1284 (1999).


31. P. A. Oldenborg, H. D. Gresham, F. P. Lindberg,J. Exp. Med.
    193 , 855–862 (2001).

ACKNOWLEDGMENTS

We thank E. Kurz, S. Valvo, L. Chen, H. Rada, M. C. Spink,

M. P. Puissegur, M. Mixon, J. Love, and A. Sessions for important

contributions to this work. We thank B. Alarcon, C. Baldari, J. Rettig,

E. Abu Shah, G. Griffiths, and F. Bravo Lopes for advice.Funding:

Supported by the ERC AdG 670930 (M.L.D.); the Wellcome

Trust 100262 (M.L.D.); the Kennedy Trust (to M.L.D. and B.M.K.);

Versus Arthritis RACE 20298 (M.L.D.); the Laboratoire d’Excellence

Toulouse Cancer (TOUCAN) under contract ANR11-LABX and

Ligue Nationale contre le Cancer (Equipe labelisée 2018) (S.V.);

the Institute for Protein Innovation; and STFC and Wellcome for

support of Diamond Light Source Ltd.Author contributions:

S.B. and M.L.D. conceived of the study and designed experiments.

S.B. performed experiments and analyzed data. S.M. and S.V.

performed CTL clone experiments. R.F. and B.M.K. acquired and

analyzed MS data. M.H. acquired and analyzed CSXT data. S.B. and

M.L.D. wrote the manuscript.Competing interests:S.B. and M.L.D.

of the University of Oxford have filed UK Patent Application No.

2005892.1 on the isolation, engineering, and use of proteinaceous

particles (SMAPs) in treatments of cancer and other disorders.

Data and materials availability:All data are available in the

manuscript or the supplementary materials.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/368/6493/897/suppl/DC1

Materials and Methods

Figs. S1 to S20

References ( 34 – 42 )

MDAR Reproducibility Checklist

Movies S1 to S14

Data S1

View/request a protocol for this paper fromBio-protocol.

29 July 2019; resubmitted 28 January 2020

Accepted 9 April 2020

Published online 7 May 2020

10.1126/science.aay9207

Bálintet al.,Science 368 , 897–901 (2020) 22 May 2020 5of5

RESEARCH | REPORT